CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing novel, masked, and conditionally activated biologics. Headquartered in South San Francisco, California, the company's core mission is to transform cancer treatment by urgently advancing its proprietary Probody® pipeline. This innovative approach aims to enable previously undruggable targets and minimize toxicity to healthy tissues, thereby destroying cancer differently.

The company leverages its Probody® technology platform to create a pipeline of therapeutics, including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Key clinical-stage candidates include Varsetatug masetecan (Varseta-M; CX-2051), an EpCAM-directed ADC for metastatic colorectal cancer and other EpCAM-expressing indications; CX-904, an EGFR x CD3 T-cell engaging bispecific antibody for solid tumors; and CX-801, an interferon alpha-2b Probody cytokine for advanced melanoma and other cancers. These programs are designed to enhance the therapeutic window and enable new combination therapies in oncology.

Led by CEO and Chairman Sean A. McCarthy, who has been with the company since 2011, CytomX Therapeutics continues to advance its pipeline and strategic collaborations. Recent notable developments include the announcement of positive Phase 1 data for Varseta-M in advanced colorectal cancer in March 2026, with plans to seek FDA alignment for a registrational trial. In March 2026, the company also commenced a public offering to raise $250.0 million to fund its pipeline. Furthermore, in June 2026, CytomX expanded its strategic research collaboration with Regeneron in the field of conditional bispecific therapeutics. The company maintains strategic partnerships with major pharmaceutical entities such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, Moderna, and Merck.